David Young
CIK 1378166 · Pres. Research & Development · last filed 2026-07-01
David Young is a Pres. Research & Development who has filed 65 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing shows the insider bought $4.9K of PCSA on Jul 1, 2026. Across all open-market trades the lifetime net is −$14.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $70.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$70.1K
3
65
-$14.49M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCSA | Pres. Research & Development | 22,971 | $3.05 | $70.1K | $382.5K | 39 | 2026-07-01 |
| QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Chief Scientific Officer | 122,366 | — | — | -$14.87M | 21 | 2014-03-18 |
| QUESTCOR PHARMACEUTICALS INC (QSC) Delisted | Director | — | — | — | $0 | 4 | 2008-01-03 |
Recent Filings
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-01 | PCSA | Buy (P) | +2,531 | $4.9K | EDGAR |
| 2026-06-16 | PCSA | Buy (P) | +2,067 | $4.6K | EDGAR |
| 2026-06-01 | PCSA | Buy (P) | +1,786 | $4.6K | EDGAR |
| 2026-05-19 | PCSA | Buy (P) | +1,545 | $4.6K | EDGAR |
| 2026-05-01 | PCSA | Buy (P) | +1,706 | $4.6K | EDGAR |
| 2026-04-17 | PCSA | Buy (P) | +1,545 | $4.6K | EDGAR |
| 2026-04-01 | PCSA | Buy (P) | +1,810 | $4.6K | EDGAR |
| 2026-02-04 | PCSA | Exer (M) | +49 | $0 | EDGAR |
| 2025-10-03 | PCSA | Grant (A) | — | $0 | EDGAR |
| 2025-09-18 | PCSA | — | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.